{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:45:34Z","timestamp":1747183534971,"version":"3.40.5"},"reference-count":41,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T00:00:00Z","timestamp":1551312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"National Institute of Health\/NCI, Cancer Center Support Grant","award":["P30 CA16672"],"award-info":[{"award-number":["P30 CA16672"]}]},{"name":"Sharpe-Strumia Research Foundation"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>In a prospective phase <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> trial, pentostatin combined with cyclophosphamide and rituximab (<jats:styled-content style=\"fixed-case\">PCR<\/jats:styled-content>) induced strong responses and was well\u2010tolerated in previously untreated patients with advanced\u2010stage, indolent non\u2010Hodgkin lymphoma (<jats:styled-content style=\"fixed-case\">iNHL<\/jats:styled-content>). After a median patient follow\u2010up of more than 108\u00a0months, we performed an intent\u2010to\u2010treat analysis of our 83 participants. Progression\u2010free survival (<jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>) rates at 108\u00a0months for follicular lymphoma (<jats:styled-content style=\"fixed-case\">FL<\/jats:styled-content>), marginal zone lymphoma (<jats:styled-content style=\"fixed-case\">MZL<\/jats:styled-content>) and small lymphocytic lymphoma (<jats:styled-content style=\"fixed-case\">SLL<\/jats:styled-content>) were 71%, 67% and 15%, respectively, and were affected by clinicopathological characteristics. Ten\u2010year <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content> rates for those with beta\u20102\u2010microglobulin levels &lt;2\u00b72 and \u22652\u00b72\u00a0mg\/l prior to treatment were 71% and 21%, respectively. Patients without bone marrow involvement had 10\u2010year <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content> rates of 72% vs. 29% for those with involvement. At time of analysis, the median overall survival (<jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>) had not been reached. The <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> rate was 64% at 10\u00a0years and differed significantly based on histology: 94% for <jats:styled-content style=\"fixed-case\">FL<\/jats:styled-content>, 66% for <jats:styled-content style=\"fixed-case\">MZL<\/jats:styled-content> and 39% for <jats:styled-content style=\"fixed-case\">SLL<\/jats:styled-content>. Long\u2010term toxicities included 18 (21\u00b77%) patients with second malignancies and 2 (2\u00b74%) who developed myelodysplastic syndrome after receiving additional lines of chemotherapy. Our 10\u2010year follow\u2010up analysis confirms that <jats:styled-content style=\"fixed-case\">PCR<\/jats:styled-content> is an effective, robust and tolerable treatment regimen for patients with <jats:styled-content style=\"fixed-case\">iNHL<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/bjh.15814","type":"journal-article","created":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T02:05:22Z","timestamp":1551405922000},"page":"670-678","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Long\u2010term overall\u2010 and progression\u2010free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non\u2010Hodgkin lymphoma"],"prefix":"10.1111","volume":"185","author":[{"given":"Tamer","family":"Khashab","sequence":"first","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"},{"name":"Department of Internal Medicine Lankenau Medical Center Wynnewood PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fredrick","family":"Hagemeister","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4830-9173","authenticated-orcid":false,"given":"Jorge E.","family":"Romaguera","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle A.","family":"Fanale","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"},{"name":"Seattle Genetics, Inc. Bothell WA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Pro","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"},{"name":"Robert H Lurie Medical Research Center Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"McLaughlin","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Alma","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sattva S.","family":"Neelapu","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Fayad","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anas","family":"Younes","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"},{"name":"Memorial Sloan Kettering Cancer Center New York NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Biostatistics The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Vega","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"},{"name":"University of Miami Sylvester Comprehensive Cancer Center Miami FL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry W.","family":"Kwak","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"},{"name":"City of Hope Hospital Duarte CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6931-4583","authenticated-orcid":false,"given":"Felipe","family":"Samaniego","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,2,28]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.7819"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.381"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07677.x"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.218"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12384"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1452214"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.0866"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26708"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.0762"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.7500"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.1495"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200013"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2005.n.039"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.4618"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2005.12.005"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-033274"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.051"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq615"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.3990"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.1652"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-2920-2"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3175"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.5376"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.4.1262"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.1112"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14541"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.7501"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-153189"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13367"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22662"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30626-X"},{"key":"e_1_2_8_37_1","first-page":"1546","article-title":"Treatment\u2010related myelodysplasia following fludarabine combination chemotherapy","volume":"91","author":"Tam C.S.","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.132035"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-624296"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-621375"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-017-0056-x"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2151"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.15814","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15814","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.15814","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15814","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T12:38:50Z","timestamp":1694349530000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,28]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.1111\/bjh.15814"],"URL":"https:\/\/doi.org\/10.1111\/bjh.15814","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"type":"print","value":"0007-1048"},{"type":"electronic","value":"1365-2141"}],"subject":[],"published":{"date-parts":[[2019,2,28]]},"assertion":[{"value":"2018-10-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}